January 14, 2014
Plandaí is Next to Ride the Marijuana Wave
Throughout 2013, management and the scientific team at Plandaí Biotechnology, Inc. (OTCQB –PLPL - $0.40 – Spec Buy) succeeded in making meaningful progress on its flagship Phytofare™ Catechin Complex and the high degree of bioavailability of the product’s nutrients to treat a host of illnesses and chronic conditions. As we have now entered 2014, the Company’s medical marijuana initiatives, announced in the fourth quarter of 2013, may take center stage now that the nation has overwhelmingly changed its stance toward broad and widespread cannabis acceptance.
In recent days, the state of Colorado has commenced the legal sale of marijuana for recreational use, and other states may elect to do so as well. Colorado expects to earn nearly $70M in annual tax revenue this year and now the state of Maryland has a legislator that believes he can get a similar bill passed. Plus, New York has now passed a medical marijuana law of its own, joining 20 other states. Moreover, a recent CNN/ORC International poll found that fully 55% of all Americans polled believe that marijuana should be legal, which is up from just 25% a decade ago. These events are not unrelated and their correlation illustrates a potential rise in interest and driver of stocks with exposure to the space in the capital markets along with a major rise in the development and use of medical marijuana.
For its part, Plandaí subsidiary, Cannabis Biosciences, Inc., will be developing and testing a botanical extract derived from cannabis, and the company its marijuana research will address neural disorders with. Specifically, the company believes that the phytonutrients in cannabis show excellent potential for treating and preventing a host of neuron and injury related brain diseases including Parkinson's, Alzheimer's, ALS, MS, epilepsy, PTSD and post-concussion syndrome.
Plandaí expects to use its licensed Phytofare™ and Pheroid™ technologies to produce an FDA approved Phytofare™ cannabinoid complex that can address neural disorders without introducing the psychoactive element of THC to its treatments. Plandaí's extraction and hydrodynamic sheering process combined with its Pheroid™ technology, should allow it to produce an extract that captures and enhances the phytocannabinoids while omitting the psychotropic effects associated with metabolized THC.
Plandaí’s near term objective is to undertake the profiling of the Phytofare™ Cannabinoid Complex with in-vitro testing starting within six months, followed by animal trials, with the expectation that it will obtain FDA consent to commence human clinical trials specifically aimed at targeted neural disorders.
As Plandaí achieves milestones events, greater awareness and attention will likely be afforded the company and its stock.
For more information, refer to our previous sponsored PLPL Reports, Updates and Hot Topics by visiting www.GoldmanResearch.com
You Might Also Like
Senior Analyst: Robert Goldman
This Opportunity Research Hot Topics article was prepared for informational purposes only.
Goldman Small Cap Research, (a division of Two Triangle Consulting Group, LLC) produces research via two formats: Goldman Select Research and Goldman Opportunity Research. The Select format reflects the Firm’s internally generated stock ideas along with economic and stock market outlooks. Opportunity Research reports, updates and Microcap Hot Topics articles reflect sponsored (paid) research but can also include non-sponsored micro cap research ideas that typically carry greater risks than those stocks covered in the Select Research category. It is important to note that while we may track performance separately, we utilize many of the same coverage criteria in determining coverage of all stocks in both research formats. Research on stocks in the Opportunity Research format typically have a higher risk profile, and may offer greater upside. Since May 2013, Goldman Small Cap Research has been compensated $500 per article by a third party and $4,000 for a research report service.
Goldman Small Cap Research is not affiliated in any way with Goldman Sachs & Co.
This article is the opinion of Goldman Small Cap Research and was written based upon publicly available information. The Company has not endorsed or compensated Goldman Small Cap Research for this article. All information contained in this report was provided by the Company or derived from GSCR due diligence. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence. Analysts are compensated on a per report basis and not on the basis of his/her recommendations.
The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. Goldman Small Cap Research relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small Cap Research report, update, article, or note is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed.
This publication does not take into account the investment objectives, financial situation, or particular needs of any particular person. This report does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA, the U.S. Securities and Exchange Commission or with any state securities regulatory authority.
ALL INFORMATION IN THIS REPORT IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.
For more information, visit our Disclaimer: www.goldmanresearch.com